HomeGeneticsGeneCDAN1 gene
Back to Gene
CDAN1 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

CDAN1 gene

The CDAN1 gene provides instructions for making the protein codanin-1, which is essential for nuclear structure and the development of red blood cells.

Normal Function

The CDAN1 gene provides instructions for making a protein called codanin-1. Research suggests that codanin-1 plays an important role in maintaining the structure of the nucleus by helping to assemble nucleosomes, which bundle DNA into a tight package. This packaging helps control gene expression.

Because codanin-1 regulates gene activity, it is involved in cell growth and the cell cycle. It is also thought to be involved in the differentiation and development of red blood cells, a process known as erythropoiesis.

Health Conditions Related to Genetic Changes

Congenital dyserythropoietic anemia

Variants in the CDAN1 gene have been identified in people with congenital dyserythropoietic anemia (CDA) type I. This condition is characterized by a shortage of red blood cells caused by abnormal red blood cell formation. In affected individuals, immature red blood cells cannot develop into functional, mature cells, leading to symptoms such as weakness, jaundice, an enlarged liver and spleen (hepatosplenomegaly), iron overload, and skeletal problems.

Most CDAN1 variants change single amino acids in the codanin-1 protein. While these variants do not completely eliminate the protein's function—as it appears essential for life—a shortage of functional codanin-1 disrupts the cell cycle during red blood cell development. Under a microscope, immature red blood cells (erythroblasts) in these patients appear abnormal, large, and multinucleated, with a speckled appearance inside the nucleus.

Other Names for This Gene

  • CDA-I
  • CDA1
  • CDAN1_HUMAN
  • codanin

Frequently Asked Questions

Yes. CDAN1 mutations are inherited in an autosomal recessive pattern, meaning both parents are carriers. Genetic counseling can explain recurrence risk (25 % for each future pregnancy), discuss carrier testing for siblings, and provide options such as prenatal diagnosis or pre‑implantation genetic testing for couples planning more children.
Diagnosis starts with a complete blood count showing anemia and a high mean corpuscular volume, followed by a bone‑marrow aspirate that reveals characteristic multinucleated, “spongy” erythroblasts. Genetic testing (sequencing of CDAN1) then confirms the diagnosis by identifying pathogenic variants. Some labs also offer targeted panels for inherited anemias that include CDAN1.
Management is largely supportive. Regular transfusions correct severe anemia, but they increase iron load, so iron chelation (e.g., deferasirox) is often required. For patients with milder disease, oral folic acid and occasional erythropoiesis‑stimulating agents may help. Splenectomy can reduce hemolysis in select cases, but it raises infection risk and is not routinely recommended. Emerging therapies such as gene‑editing are experimental and not yet clinically available.
Monitor ferritin and liver iron concentration every 6‑12 months. If ferritin exceeds 1,000 ng/mL or MRI shows hepatic iron >7 mg/g, start an oral chelator (deferasirox) or an intravenous agent (deferoxamine) as directed by a hematologist. Dietary iron restriction has limited effect, but avoiding excess vitamin C supplements (which increase iron absorption) is prudent. Regular phlebotomy is usually avoided because patients are already anemic.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab

Sök
Om ossVillkor och policyVanliga frågorKontakta oss